Aptevo Therapeutics Inc. 8-K

What Happened

• Aptevo Therapeutics Inc. announced its financial results for the period ended December 31, 2025 by issuing a press release on March 26, 2026. The company furnished the press release as Exhibit 99.1 to an SEC Form 8-K (Item 2.02), which reports results of operations and financial condition. The filing was signed by President and CEO Marvin L. White.

Key Details

• Filing date: March 26, 2026; reporting period: December 31, 2025.
• The press release containing the earnings/financial results is attached as Exhibit 99.1 to the Form 8-K.
• The information in the Form 8-K and Exhibit 99.1 was furnished (not “filed”) and therefore is not subject to Section 18 liability or Sections 11 and 12(a)(2) of the Securities Act.
• The Form 8-K was signed by Marvin L. White, President and Chief Executive Officer.

Why It Matters

• This filing signals that Aptevo has publicly released its recent quarterly/period financial results; investors should review the attached press release (Exhibit 99.1) for revenue, earnings, guidance, and other specific metrics.
• Because the release was furnished rather than filed, its contents are not automatically incorporated by reference into other SEC filings, which is important for how the company’s disclosures are treated legally.
• Retail investors should read the press release and watch for any follow-up filings (e.g., quarterly report or earnings call) for full financial detail and context.